Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy. (2025). Farmeconomia. Health Economics and Therapeutic Pathways, 26(1). https://doi.org/10.7175/fe.v26i1.1574